Kenya Confirms Eighth Ebola Case as Regional Outbreak Spurs Border Controls
Kenya confirms its eighth Ebola case as health authorities ramp up border screenings and contact tracing. Meanwhile, the DRC faces the deadliest outbreak in its history driven by the rare Bundibugyo strain.
Kenya's Ministry of Health confirmed on Sunday that an eighth Ebola case has been diagnosed in the country. The new patient, a 49-year-old support staff worker, had been in isolation since being identified as a contact of the first patient—a Kenyan citizen who arrived from the Democratic Republic of Congo and died earlier this month.
Quarantine Measures and Contact Tracing
Dr. Patrick Amoth, Director-General of Health, stated that the new patient is not a medical professional. His duties involved cleaning equipment and linens, and he was reportedly exposed while handling the first patient. On Saturday, he developed a fever, headaches, and muscle aches, prompting immediate separation from other quarantined individuals. Out of 38 people tested on Sunday, one returned a positive result.
The condition of the other six patients—three relatives and three medical staff members—remains stable under supportive care. Following the death of the index case, approximately 130 contacts were identified, with 128 remaining in isolation. The index case, a 40-year-old Kenyan man residing in Congo, traveled through three affected provinces before flying to Nairobi. His arrival exposed significant gaps in border screening protocols, prompting heightened checks, a dedicated hotline, and specific airport gates for flights from high-risk nations.
Regional Spread and Vaccine Trials
Kenya is the fourth country to report cases in this ongoing outbreak. Meanwhile, the DRC continues to battle the worst and fastest-spreading outbreak in its history, driven by the rare Bundibugyo strain. With no approved vaccine or specific treatment for this strain, health authorities are relying on supportive care while testing existing countermeasures. DRC has received 70,000 doses of the Ervebo vaccine—approved for the Zaire strain—to protect frontline workers and conduct Phase 3 trials.
Additionally, human trials have begun for a novel Oxford University vaccine specifically targeting the Bundibugyo strain, alongside an experimental mRNA vaccine developed by Moderna. The World Health Organization previously warned that surrounding nations remain at high risk of regional dissemination.
